BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.

Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.

Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16407622.001).

[ISSN] 1590-8577

[Journal-full-title] JOP : Journal of the pancreas

[ISO-abbreviation] JOP

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Haematoxylin and Eosin stained slides were examined to determine the histological type, grade and stage of CRC.

RESULTS: Among the 100 cases, 59 were non mucinous adenocarcinomas, of which 4 were in Dukes' stage A, 51 were in Dukes' stage B and 4 were in Dukes' stage C.

In thirty cases of mucinous carcinomas, 18 were in Dukes' stage B and 12 were in Dukes' stage C, of these 2 were of grade I, 20 were of grade II and 8 were of grade III.

All the 11 signet ring cell carcinomas were of grade III and in Dukes' stage C.

CONCLUSION: Mucin secreting and signet-ring cell adenocarcinomas of colon and rectum are high grade tumours and presented at an advanced stage.

[MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Neoplasm Staging

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21381550.001).

[ISSN] 0030-9982

[Journal-full-title] JPMA. The Journal of the Pakistan Medical Association

[ISO-abbreviation] J Pak Med Assoc

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] Pakistan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.

RATIONALE: The aim of this study was to assess whether there are differences in treatment strategy and outcome between different age cohorts among men and women with colon cancer.

METHODS: All patients with colon cancer included in the regional quality registry in Uppsala/Orebro and Stockholm between 1996 and December 2004 were analysed (n=11002).

RESULTS: Overall and cancer-specific survival decreased with increasing age for stages II and III colon cancer but was not influenced by gender.

Older patients with stage III tumours were less likely to be referred for chemotherapeutic treatment and there was a decrease in cancer-specific survival with increasing age, from 63.7% to 51.0% to 38.4% in the three age groups.

[MeSH-minor] Adenocarcinoma. Age Distribution. Age Factors. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Sex Factors. Survival Analysis. Sweden. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18440820.001).

[ISSN] 1040-8428

[Journal-full-title] Critical reviews in oncology/hematology

[ISO-abbreviation] Crit. Rev. Oncol. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PATIENTS AND METHODS: MSI and KRAS mutation status were assessed in 532 primary adenocarcinomas (stage I-IV) from patients treated by colon resection.

MSI was more common in early-stage disease (I, 15%; II, 21%; III, 10%; IV, 2%; P = 0.0001).

Prevalence of KRAS mutation did not vary with stage (I, 36%; II, 34%; III, 35%; IV, 40%; P = ns).

Using Cox regression analysis MSI, KRAS mutation, and stage were strong independent predictors of survival in the entire patient population.

A high-mortality group with MSS/KRAS-mutant tumors was identified within the stage I and II cohort.

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19813061.001).

[ISSN] 1534-4681

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA065930; United States / NCI NIH HHS / CA / 2 P01 CA65930-05A2

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins

[Other-IDs] NLM/ NIHMS674393; NLM/ PMC4380015

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.

Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.

[MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

Genetic Alliance. consumer health - Metastatic cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16314630.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.

PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.

CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]

[Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]

[Cites] Cancer Control. 1995 Mar;2(2 Suppl 1):36-38 [10887408.001]

[Cites] Pharmacol Rev. 2004 Jun;56(2):163-84 [15169926.001]

[Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]

[Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]

[Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]

[Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]

[Cites] Ann Oncol. 2004 Apr;15(4):568-73 [15033660.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] Am J Clin Oncol. 2003 Feb;26(1):103-6 [12576935.001]

[Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]

[Cites] Ann Oncol. 2005 May;16(5):767-72 [15817594.001]

[Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]

[Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]

[Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]

[Cites] Am J Clin Oncol. 1982 Apr;5(2):227-36 [7091044.001]

[Cites] Ann Oncol. 2000 Aug;11(8):947-55 [11038030.001]

[Cites] J Clin Oncol. 1984 Jul;2(7):849-55 [6737023.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]

[Cites] Cancer. 1995 Feb 1;75(3):775-81 [7828127.001]

[Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]

[Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

(PMID = 17303911.001).

[ISSN] 1357-0560

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.

BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.

MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.

There was no difference between the two groups when analysed for colon and rectum separately.

However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.

CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19242829.001).

[ISSN] 1651-226X

[Journal-full-title] Acta oncologica (Stockholm, Sweden)

[ISO-abbreviation] Acta Oncol

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] Norway

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].

OBJECTIVE: Colon cancer is the third most common cancer in Iceland.

The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.

MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.

Most tumors were located in the sigmoid colon (35%).

Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.

Altogether 7% of cases were TNM-stage I, 32% were stage II, 24% stage III, 21% in stage IV and stage was unknown in 16% of cases.

CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.

Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.

[MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]

(PMID = 19491407.001).

[ISSN] 0023-7213

[Journal-full-title] Læknablađiđ

[ISO-abbreviation] Laeknabladid

[Language] ice

[Publication-type] Comparative Study; English Abstract; Journal Article

[Publication-country] Iceland

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).

METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.

37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.

CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.

[MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy

[MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16885869.001).

[ISSN] 0399-8320

[Journal-full-title] Gastroentérologie clinique et biologique

[ISO-abbreviation] Gastroenterol. Clin. Biol.

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

High-frequency microsatellite instability has been reported to be associated with good prognosis in colorectal adenocarcinoma.

Clinicopathological features of a cohort of 204 patients with primary colon cancer were retrospectively reviewed following predetermined criteria.

Implementation of this tool to routine histopathological studies could improve the management of patients with colorectal cancer, especially those presenting with stage II and III of the disease.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16319691.001).

[ISSN] 1052-9551

[Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B

[ISO-abbreviation] Diagn. Mol. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Ki-67 Antigen

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan.

BACKGROUND: Colon cancer is a common malignancy with its incidence reportedly rising in Asian countries, including Pakistan.

There are no comprehensive data available from Pakistan which focus on associations of various factors with long-term survival of colon cancer.

METHODOLOGY: In this retrospective study adult patients with colon cancer diagnosed through 2000-2003 were included.

Of the total, 49.5% of the patients had right sided (mortality rate 51.6%), 10.8% had transverse colon, (mortality rate 37.5%), 7.5% had descending colon (mortality rate 66.7%) and 32.2% had sigmoid colon (mortality rate 40.9%) cancers.

Stage I disease on diagnosis was found in 16%, stage II in 42.7 (mortality 40 %) and stage III in 41.3% (mortality 70 %).

Most patients had pure adenocarcinoma while a mucinous type differentiation was seen in 19.7%, 3% had signet ring morphology, 1.5% adeno-squamous carcinoma and similar number with neuroendocrine differentiation.

CONCLUSION: Colon cancer in Pakistan commonly presents at an advanced stage, there is a male preponderance, and relatively mean younger age at presentation for males is seen.

Advanced stage and lymph node involvement along with poorly differentiated pathology, signet ring or mucinous morphology, location in descending colon, positive surgical margins and removal of less than twelve lymph nodes are factors associated with poor long term survival.

There is a need to reinforce information about colon cancer and larger studies from the region are needed to confirm the factors analyzed here.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Survivors

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19640173.001).

[ISSN] 2476-762X

[Journal-full-title] Asian Pacific journal of cancer prevention : APJCP

[ISO-abbreviation] Asian Pac. J. Cancer Prev.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Thailand

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] Bronchiolite oblitérante avec pneumonie organisée après chimiothérapie de type FOLFOX 4.

INTRODUCTION: FOLFOX 4 chemotherapy (5-fluorouracil, leucovorin and oxaliplatin) is the standard adjuvant treatment for stage III colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / toxicity. Colonic Neoplasms / drug therapy. Cryptogenic Organizing Pneumonia / chemically induced

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20146958.001).

[ISSN] 1776-2588

[Journal-full-title] Revue des maladies respiratoires

[ISO-abbreviation] Rev Mal Respir

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

[Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: A total of 542 patients survived a radical resection for Stages I, II, or III colorectal cancer.

Differences in overall survival also were found when patients in Stages I, II, and III were analyzed separately.

Risk factors for overall survival were advanced stage of disease, poor tumor differentiation, mucinous adenocarcinoma, older than age 70 years, and poor condition of the patient at time of operation.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16550320.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The five-year disease-free survival rates classified according to the TNM stage were 100 percent for stage I, 83.5 percent for stage II, and 72.0 percent for stage III cases.

[MeSH-major] Adenocarcinoma / surgery. Rectal Neoplasms / surgery

Genetic Alliance. consumer health - Rectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19581848.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.

Moreover, an altered p53/BAX pathway is associated with a poor clinical outcome in Union Internationale Contre le Cancer (UICC) stage III disease.

PATIENTS AND METHODS: Specimens were analyzed from 59 patients with UICC stage III disease who underwent surgery for colorectal adenocarcinoma at our institution and were followed up for 5 years or until death.

RESULTS: p53 status/BAX expression and neuroendocrine differentiation are not correlated in stage III colorectal cancers.

Both represent independent prognostic markers in UICC stage III disease.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann N Y Acad Sci. 1994 Sep 15;733:46-55 [7978895.001]

[Cites] Leukemia. 2001 Jul;15(7):1022-32 [11455969.001]

[Cites] Int J Cancer. 2000 Aug 15;87(4):517-21 [10918191.001]

[Cites] Acta Oncol. 1993;32(2):115-24 [8323752.001]

[Cites] Clin Cancer Res. 2002 Oct;8(10):3205-9 [12374690.001]

[Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]

[Cites] Leukemia. 2000 Dec;14(12):2035-44 [11187890.001]

[Cites] Essays Biochem. 2003;39:73-88 [14585075.001]

[Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]

[Cites] Int J Cancer. 2000 Oct 15;88(2):281-6 [11004681.001]

[Cites] Br J Cancer. 2001 Mar 2;84(5):651-8 [11237386.001]

[Cites] Int J Cancer. 2002 Jun 1;99(4):589-96 [11992551.001]

[Cites] J Clin Pathol. 1995 Aug;48(8):754-8 [7560204.001]

[Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]

[Cites] Ann Surg Oncol. 1996 Nov;3(6):574-9 [8915491.001]

[Cites] Int J Cancer. 1993 Jul 9;54(5):765-71 [8100808.001]

[Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]

[Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]

[Cites] Cancer. 1991 Apr 1;67(7):1859-61 [2004298.001]

[Cites] Oncogene. 2001 May 17;20(22):2749-60 [11420687.001]

[Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]

[Cites] Anticancer Res. 2001 Jan-Feb;21(1A):253-9 [11299743.001]

[Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1011-9 [11772231.001]

[Cites] Gut. 2004 Jun;53(6):899-910 [15138220.001]

[Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]

[Cites] APMIS. 2004 Jan;112(1):49-56 [14961975.001]

[Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]

[Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]

[Cites] Int J Cancer. 2002 Feb 1;97(4):403-9 [11802199.001]

[Cites] World J Surg. 2002 Jan;26(1):59-66 [11898035.001]

[Cites] Cancer. 1992 Jun 1;69(11):2641-6 [1571893.001]

[Cites] Dis Colon Rectum. 2001 Apr;44(4):523-33 [11330579.001]

[Cites] Eur J Clin Invest. 1998 Dec;28(12):1038-49 [9893017.001]

[Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]

[Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]

[Cites] Physiol Rev. 1988 Apr;68(2):456-502 [3282244.001]

[Cites] Digestion. 2000;62 Suppl 1:3-18 [10940682.001]

[Cites] J Biol Chem. 2004 Jan 16;279(3):1713-9 [14593113.001]

[Cites] Int J Cancer. 2003 Feb 10;103(4):445-54 [12478659.001]

[Cites] Int J Cancer. 1995 Mar 3;60(5):645-51 [7860139.001]

[Cites] Cancer Res. 2000 Aug 15;60(16):4573-81 [10969809.001]

[Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(5):293-6 [8287125.001]

[Cites] J Biol Chem. 2002 Aug 2;277(31):27643-50 [12011069.001]

[Cites] Histopathology. 1998 Feb;32(2):133-8 [9543669.001]

[Cites] Arch Pathol Lab Med. 2001 Jan;125(1):91-8 [11151060.001]

[Cites] Arch Pathol Lab Med. 1998 Oct;122(10):912-4 [9786353.001]

[Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]

[Cites] J Clin Oncol. 2003 Sep 15;21(18):3391-401 [12885834.001]

(PMID = 16485142.001).

[ISSN] 0179-1958

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / bcl-2-Associated X Protein

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Case of adenosquamous carcinoma of the ascending colon.

Adenocarcinoma accounts for most of the malignant tumors originating from the colon, whereas adenosquamous carcinoma is rare, accounting for about 0.1% of all colon cancers.

We present herein a case of adenosquamous carcinoma of the ascending colon.

A barium enema examination and lower gastrointestinal endoscopy showed a type 3 tumor in the ascending colon, and a biopsy confirmed the diagnosis of adenosquamous carcinoma.

Right hemicolectomy was performed, and the tumor was diagnosed as a stage III advanced colon cancer.

A search of Japanese literature over the past 25 years yielded 70 patients with adenosquamous carcinoma of the colon, and the clinicopathological features are discussed herein.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18781050.001).

[ISSN] 1345-4676

[Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

[ISO-abbreviation] J Nippon Med Sch

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PURPOSE: The prognosis varies greatly in colorectal carcinoma patients, even in the same stage.

In different stages, coexpression tumor markers functioned in Stages II and III but not in the 19 cases of Stage I.

[MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / nursing. Carcinoembryonic Antigen / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / mortality. Intracellular Signaling Peptides and Proteins / metabolism. Matrix Metalloproteinase 2 / metabolism

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17882488.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Carcinoembryonic Antigen; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.4.24.24 / Matrix Metalloproteinase 2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Radiation-Sensitizing Agents / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

Genetic Alliance. consumer health - Rectal Cancer.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CAPECITABINE .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]

[Cites] Bioorg Med Chem. 2000 Jul;8(7):1697-706 [10976516.001]

[Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]

[Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]

[Cites] Clin Ther. 2004 Apr;26(4):579-89 [15189755.001]

[Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]

[Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]

[Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]

[Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]

[Cites] Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-8-S18-18 [9420016.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]

[Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]

[Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]

[Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]

[Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]

(PMID = 17042060.001).

[ISSN] 1332-8166

[Journal-full-title] Croatian medical journal

[ISO-abbreviation] Croat. Med. J.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] Croatia

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2080466

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We evaluated ypTNM stage and tumoral regression, according to the five degrees proposed by Dworak, with special attention to 4 and 3 (sterilized and minimal residual disease).

[MeSH-major] Adenocarcinoma / therapy. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Neoplasm, Residual / epidemiology. Rectal Neoplasms / therapy

Genetic Alliance. consumer health - Rectal Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16132481.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.

Ten patients (18 percent) had an American Society of Anesthesiologists' classification of III.

The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).

The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.

Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.

At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.

Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).

[MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18679748.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Interactive Tutorial

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers.

OBJECTIVE: Colon cancers with high frequency microsatellite instability (MSI-H) are preferentially located in the proximal colon.

Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases.

METHODS: TNM stage II and III primary colon carcinomas (N = 528) from patients enrolled in 5-fluorouracil-based adjuvant trials were analyzed for MSI using 11 microsatellite markers.

RESULTS: MSI-H was found in 95 (18%) colon cancers.

CONCLUSIONS: Tumor site-related differences in clinicopathological variables, biomarkers, and prognosis of sporadic colon cancers can be explained by the inclusion of MSI-H cases.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17026563.001).

[ISSN] 0002-9270

[Journal-full-title] The American journal of gastroenterology

[ISO-abbreviation] Am. J. Gastroenterol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA074800; United States / NCI NIH HHS / CA / CA 104683

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.

PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.

METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.

CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.

[MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

Genetic Alliance. consumer health - Metastatic cancer.

Hazardous Substances Data Bank. MITOMYCIN C .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16625329.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.

BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.

METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.

RESULTS: The overall survival (OS) in stage II patients was greater with the higher number of lymph node (LN) examined.

For stage II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).

For stage III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).

CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17693281.001).

[ISSN] 1879-1883

[Journal-full-title] American journal of surgery

[ISO-abbreviation] Am. J. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.

The results of a phase III trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%.

Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal / therapeutic use. Colorectal Neoplasms / pathology

Genetic Alliance. consumer health - Colorectal Cancer.

Genetic Alliance. consumer health - Metastatic cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Clin Colorectal Cancer. 2006 May;6(1):13 [16796785.001]

(PMID = 16796788.001).

[ISSN] 1533-0028

[Journal-full-title] Clinical colorectal cancer

[ISO-abbreviation] Clin Colorectal Cancer

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / panitumumab

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Sixteen HG-U133A oligonucleotide microarrays were analysed including four of colonic polyps, four of adenocarcinoma with different degree of histological differentiation (2 poorly and 2 highly differentiated), and eight of macroscopically normal tissue.

An analysis of all per cent variability values with regard to malignancy stage increasing from polyp to stages I to III adenocarcinoma, and normal colon mucosa shows a statistically significant relationship for TLR2 (increasing) and TLR3 (decreasing).

In normal colon mucosa of polyposis patients the highest mRNA copy numbers were observed for TLR3, and the lowest for TLR7.

TLR3 may serve as a marker of colon tissue metaplasia and may indicate the tendency of normal tissue to form polyps transforming to colorectal cancer.

[MeSH-major] Adenocarcinoma / metabolism. Colonic Polyps / metabolism. Colorectal Neoplasms / metabolism. Mucous Membrane / metabolism. Toll-Like Receptors / biosynthesis

[MeSH-minor] Adult. Aged. Colon / metabolism. Colon / pathology. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colonic Polyps.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19609015.001).

[ISSN] 1899-1505

[Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

[ISO-abbreviation] J. Physiol. Pharmacol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Poland

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Toll-Like Receptors

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The class III histone deacetylase SIRT1 (sir2) is important in epigenetic gene silencing.

SIRT1 was not significantly related with age, sex, tumor location, stage, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, beta-catenin, COX-2, or patient prognosis.

In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] PLoS One. 2008;3(4):e2020 [18414679.001]

[Cites] Int J Cancer. 2008 Jun 15;122(12):2767-73 [18366060.001]

[Cites] Neoplasia. 2008 Jun;10(6):534-41 [18516290.001]

[Cites] Cancer Lett. 2008 Sep 18;268(2):177-86 [18471961.001]

[Cites] PLoS One. 2008;3(11):e3698 [19002263.001]

[Cites] Mod Pathol. 2008 Dec;21(12):1533-41 [18849918.001]

[Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8 [19033568.001]

[Cites] J Clin Oncol. 2008 Dec 10;26(35):5713-20 [18955444.001]

[Cites] Mod Pathol. 2008 Nov;21(11):1403-12 [18587323.001]

[Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]

[Cites] Mod Pathol. 2009 Jan;22(1):151-60 [19011600.001]

[Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]

[Cites] Stat Med. 1989 May;8(5):551-61 [2657958.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]

[Cites] Science. 2004 Dec 17;306(5704):2105-8 [15604409.001]

[Cites] Cell. 2005 Feb 25;120(4):473-82 [15734680.001]

[Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]

[Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]

[Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]

[Cites] Gastroenterology. 2005 Sep;129(3):1121-4 [16143149.001]

[Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]

[Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]

[Cites] PLoS Genet. 2006 Mar;2(3):e40 [16596166.001]

[Cites] Nat Genet. 2006 May;38(5):566-9 [16642021.001]

[Cites] J Mol Diagn. 2006 May;8(2):209-17 [16645207.001]

[Cites] PLoS Genet. 2005 Dec;1(6):e77 [16362078.001]

[Cites] Gut. 2006 Jul;55(7):1000-6 [16407376.001]

[Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]

[Cites] J Mol Diagn. 2006 Nov;8(5):582-8 [17065427.001]

[Cites] Mod Pathol. 2007 Jan;20(1):15-22 [17086168.001]

[Cites] Mod Pathol. 2007 Mar;20(3):375-83 [17277760.001]

[Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]

[Cites] Genes Dev. 2000 May 1;14(9):1021-6 [10809662.001]

[Cites] Nature. 2000 Nov 9;408(6809):255-62 [11089983.001]

[Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]

[Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]

[Cites] EMBO J. 2002 May 15;21(10):2383-96 [12006491.001]

[Cites] Nat Genet. 2002 Nov;32(3):378-83 [12379856.001]

[Cites] Nat Genet. 2002 Nov;32(3):370-7 [12410229.001]

[Cites] Cancer Res. 2002 Nov 1;62(21):6011-4 [12414620.001]

[Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]

[Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]

[Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]

[Cites] Nat Rev Genet. 2007 Apr;8(4):286-98 [17339880.001]

[Cites] Biochem J. 2007 May 15;404(1):1-13 [17447894.001]

[Cites] Cancer J. 2007 Jan-Feb;13(1):49-55 [17464246.001]

[Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]

[Cites] J Mol Diagn. 2007 Jul;9(3):305-14 [17591929.001]

[Cites] Neoplasia. 2007 Jul;9(7):569-77 [17710160.001]

[Cites] Gut. 2007 Nov;56(11):1498-500 [17938428.001]

[Cites] Mod Pathol. 2007 Nov;20(11):1183-90 [17873897.001]

[Cites] Nat Rev Genet. 2007 Nov;8(11):829-33 [17909537.001]

[Cites] Nat Rev Genet. 2007 Nov;8(11):835-44 [17909538.001]

[Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]

[Cites] J Mol Diagn. 2008 Jan;10(1):13-27 [18165277.001]

[Cites] Carcinogenesis. 2008 Feb;29(2):434-9 [18048385.001]

[Cites] Epigenetics. 2008 Jan-Feb;3(1):28-37 [18326939.001]

[Cites] Mod Pathol. 2008 May;21 Suppl 2:S23-30 [18437170.001]

(PMID = 19430421.001).

[ISSN] 1530-0285

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / K07 CA122826-02; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / CA122826-02; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / CA055075-15; United States / NCI NIH HHS / CA / P50 CA127003-02; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P01 CA055075-15

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins

[Other-IDs] NLM/ NIHMS100427; NLM/ PMC2704253

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.

The increase of COX-2 was also correlated to stage (FIGO classification) with significant elevations in stages II and III.

EP1 was increased in stage III while no significant alterations were demonstrated for COX-1, mPGES-1 or EP2 for stage.

[MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

Genetic Alliance. consumer health - Ovarian cancer.

Genetic Alliance. consumer health - Ovarian epithelial cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]

[Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]

[Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]

[Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]

[Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]

[Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]

[Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]

[Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]

[Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]

[Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]

[Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]

[Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]

[Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]

[Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]

[Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]

[Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]

[Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]

[Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]

[Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]

[Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]

[Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]

[Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]

[Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]

[Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]

[Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]

[Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]

[Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]

[Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]

[Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]

[Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]

[Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]

[Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]

[Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]

[Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]

[Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]

[Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]

[Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]

[Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]

[Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]

[Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]

[Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]

[Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]

[Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]

[Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]

[Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]

[Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]

[Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]

[Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]

[Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]

[Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]

(PMID = 17107625.001).

[ISSN] 1476-4598

[Journal-full-title] Molecular cancer

[ISO-abbreviation] Mol. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone

[Other-IDs] NLM/ PMC1657027

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.

The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage.

Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy.

Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage.

Seventy-one patients (28%) showed complete clinical response (clinical stage 0).

In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease.

Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0.

Disease-free survival rate showed better results in stage c0, but the results were not significant.

Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively.

Also, stage 0 is significantly associated with improved outcome.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Neoadjuvant Therapy. Rectal Neoplasms / mortality. Rectal Neoplasms / surgery

Genetic Alliance. consumer health - Rectal Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]

[Cites] Br J Surg. 2003 Aug;90(8):999-1003 [12905555.001]

[Cites] J Gastrointest Surg. 2004 Jan;8(1):56-62; discussion 62-3 [14746836.001]

[Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]

[Cites] Eur J Surg Oncol. 2001 Jun;27(4):349-53 [11417978.001]

[Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]

[Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]

[Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]

[Cites] Rev Invest Clin. 2001 Jan-Feb;53(1):65-76 [11332053.001]

[Cites] Br J Surg. 2001 Jul;88(7):988-93 [11442533.001]

[Cites] World J Surg. 2001 Aug;25(8):1006-11 [11571965.001]

[Cites] Br J Surg. 1986 Sep;73(9):732-5 [3756437.001]

[Cites] Cancer. 2002 Feb 15;94(4):1121-30 [11920483.001]

[Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]

[Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]

[Cites] J Clin Oncol. 1995 Jun;13(6):1417-24 [7751887.001]

[Cites] Dis Colon Rectum. 1997 May;40(5):515-22 [9152176.001]

[Cites] Dis Colon Rectum. 2001 Aug;44(8):1123-8 [11535851.001]

[Cites] Dis Colon Rectum. 2000 Dec;43(12):1695-1701; discussion 1701-3 [11156453.001]

[Cites] Radiother Oncol. 1999 May;51(2):153-60 [10435807.001]

[Cites] J Surg Oncol. 2003 Jul;83(3):133-9 [12827680.001]

[Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]

[Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]

[Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]

[Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]

[Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]

[Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]

[Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):21-7 [9588913.001]

[Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]

(PMID = 15623449.001).

[ISSN] 1091-255X

[Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

[ISO-abbreviation] J. Gastrointest. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

1) epithelial ovarian cancer, stage II-III (n = 89);.

3) breast (n = 10), colon (n = 10), and stomach (n = 10) cancers; and 4) controls (n = 95).

In four cases of women with stage IIC mucinous tumor, blood specimens were collected during the follow-up time.

[MeSH-major] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / blood. Immunoenzyme Techniques / methods. Inhibins / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

[MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cross-Sectional Studies. Epithelium / pathology. Female. Humans. Middle Aged. ROC Curve

Genetic Alliance. consumer health - Ovarian cancer.

Genetic Alliance. consumer health - Ovarian epithelial cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17473066.001).

[ISSN] 0021-972X

[Journal-full-title] The Journal of clinical endocrinology and metabolism

[ISO-abbreviation] J. Clin. Endocrinol. Metab.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 57285-09-3 / Inhibins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour of colon cancers than does EGFR expression.

However, the prognostic effect of phospho-EGFR in primary colon cancer remains undefined.

METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).

Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).

Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.

EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

COS Scholar Universe. author profiles.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Hazardous Substances Data Bank. FLUOROURACIL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]

[Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]

[Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]

[Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]

[Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]

[Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]

[Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]

[Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]

[Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]

[Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]

[Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]

[Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]

[Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]

[Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]

[Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]

[Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]

[Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]

[Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]

[Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]

[Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]

[Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]

[Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]

[Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]

[Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]

[Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]

[Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]

[Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]

[Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]

[Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]

[Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]

[Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]

[Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]

[Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]

[Cites] Pathology. 2009;41(4):356-60 [19404848.001]

[Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]

[Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]

[Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]

[Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]

[Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]

[Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]

[Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]

[Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]

[Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]

[Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]

[Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]

[Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]

(PMID = 19997103.001).

[ISSN] 1532-1827

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] ENG

[Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2813748

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer.

Estrogen receptor beta (ERβ) is the most highly expressed protein in patients with colon cancer.

We have previously shown that endocrine therapy can inhibit MMP7 expression in colon cancer cells.

In this study, we aim to identify the prognostic effects and correlation of ERβ and MMP7 in the context of colon cancer.

ERβ and MMP7 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 423 patients with stage I-III colon cancer.

In the subset of patients with high expression levels of tumoral nuclear ERβ, high expression of MMP7 was related to OS and CSS among colon cancer patients with high expression of ERβ.

In conclusion, our results suggest that low expression of ERβ was a risk factor in colon cancer, and high expression of MMP7 was an independent prognostic factor of ERβ-positive patients with colon cancer.

[MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Colonic Neoplasms / metabolism. Colonic Neoplasms / mortality. Estrogen Receptor beta / metabolism. Matrix Metalloproteinase 7 / metabolism

antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg. 2001 Jun;233(6):786-92 [11371737.001]

[Cites] J Invest Dermatol. 1995 Aug;105(2):190-6 [7636300.001]

[Cites] Eur J Cancer. 2003 Jun;39(9):1251-8 [12763213.001]

[Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]

[Cites] Hum Pathol. 2001 Sep;32(9):940-4 [11567223.001]

[Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]

[Cites] Oncol Rep. 2005 Jul;14(1):17-21 [15944762.001]

[Cites] Endocr Relat Cancer. 2004 Sep;11(3):537-51 [15369453.001]

[Cites] J Exp Clin Cancer Res. 2009 Sep 29;28:132 [19785773.001]

[Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]

[Cites] Endocr Relat Cancer. 2005 Jun;12(2):455-69 [15947116.001]

[Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Dig Dis Sci. 2002 Dec;47(12):2720-8 [12498292.001]

[Cites] Cell Oncol. 2009;31(3):235-47 [19478391.001]

[Cites] Cancer Res. 2000 Jan 15;60(2):245-8 [10667568.001]

[Cites] Int J Colorectal Dis. 2009 Aug;24(8):875-84 [19421758.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2959-64 [16477031.001]

[Cites] J Pathol. 2005 Sep;207(1):53-60 [15954165.001]

(PMID = 20680712.001).

[ISSN] 1423-0380

[Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

[ISO-abbreviation] Tumour Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; EC 3.4.24.23 / Matrix Metalloproteinase 7

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The study subjects were tumor, node, metastasis system stage III rectosigmoid cancer staged by clinical images.

The extent of D3 dissection and the postoperative lymph node mapping were according to the guidelines of the Japanese Society for Cancer of the Colon and Rectum.

CONCLUSIONS: The good short-term oncologic results and quick convalescence mean that the laparoscopic D3 dissection may be recommended for patients with stage III rectosigmoid cancer who could accept the genitourinary dysfunction.

[MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision / methods. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery

Genetic Alliance. consumer health - Rectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17458586.001).

[ISSN] 1068-9265

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.

To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.

The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.

In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.

Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16422269.001).

[ISSN] 0043-3284

[Journal-full-title] The West Virginia medical journal

[ISO-abbreviation] W V Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression.

We report on a patient who developed far-ranging metastases of adenocarcinoma of the colon that followed a gradual cephalad progression, including the right external ear canal, and led to hearing loss.

The patient was a 63-year-old white male with stage III adenocarcinoma of the colon.

Physical examination of the head and neck showed a mass in the external ear canal, and biopsy confirmed adenocarcinoma.

The significance of such wide-ranging metastases is that metastasis of adenocarcinoma to the ear did not signal imminent death, and relief of the hearing loss it caused was possible.

[MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ear Canal. Ear Neoplasms / secondary

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15742771.001).

[ISSN] 0145-5613

[Journal-full-title] Ear, nose, & throat journal

[ISO-abbreviation] Ear Nose Throat J

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.

We studied 68 sporadic colorectal carcinomas (CRCs) with medullary features (MCRCs) and compared them with 35 poorly differentiated purely "enteric" CRCs (ECRCs) and 15 purely neuroendocrine carcinomas (NECs) of grades II and III, all in patients lacking a family history of CRC.

MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.

Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15762280.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship.

PATIENTS: Patients aged 66 years and older, diagnosed and surgically treated for stage I, II, or III colon cancer between 1992 and 1996 (n = 22 672).

[MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / utilization. Hospitals / utilization. Outcome Assessment (Health Care)

MedlinePlus Health Information. consumer health - Health Facilities.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17224497.001).

[ISSN] 0004-0010

[Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)

[ISO-abbreviation] Arch Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma.

METHODS: We analyzed 480 positive lymph nodes from 155 consecutive patients with Stage III colorectal cancer to determine the frequency and significance of lymph node capsular invasion.

CONCLUSIONS: Lymph node capsular invasion, determined by routine hematoxylin-eosin staining, is a potent prognostic factor in Stage III colorectal cancer.

[MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology

MedlinePlus Health Information. consumer health - Colorectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Dis Colon Rectum. 2007 Sep;50(9):1484; author reply 1484-5 [17661142.001]

(PMID = 17080279.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.

OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.

MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.

In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.

Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.

CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

Genetic Alliance. consumer health - Metastatic cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Clin Oncol. 2004 Jun;27(3):304-6 [15170153.001]

[Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]

[Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]

[Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]

[Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]

[Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]

[Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]

[Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]

[Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]

[Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]

[Cites] Ann Surg Oncol. 2008 Jun;15(6):1600-8 [18327530.001]

[Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]

[Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]

[Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Cancer. 1967 Nov;20(11):1976-85 [6061631.001]

[Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]

(PMID = 19479270.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study.

We aimed to assess the quality of colon cancer surgery by studying the extent of variation in the plane of surgical resection, the amount of tissue removed, and its association with survival.

METHODS: All resections for primary colon adenocarcinoma done at Leeds General Infirmary (Leeds, UK) between Jan 1, 1997, and June 30, 2002, were identified.

However, this association was no longer significant in the multivariate model (HR 0.86 [95% CI 0.56-1.31], p=0.472), but was especially noted in patients with stage III cancers (HR 0.45 [95% CI 0.24-0.85], p=0.014; multivariate analysis).

INTERPRETATION: As previously shown in the rectum, we have now shown there is marked variability in the plane of surgery achieved in colon cancer.

Improving the plane of dissection might improve survival, especially in patients with stage III disease.

If confirmed by clinical trial data, such as from the ongoing National Cancer Research Institute Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dissection might be a new cost-effective method of decreasing morbidity and mortality in patients with colon cancer.

[MeSH-major] Adenocarcinoma / surgery. Colectomy / standards. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / prevention & control. Quality of Health Care

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Lancet Oncol. 2008 Sep;9(9):815-7 [18760238.001]

(PMID = 18667357.001).

[ISSN] 1474-5488

[Journal-full-title] The Lancet. Oncology

[ISO-abbreviation] Lancet Oncol.

[Language] eng

[Grant] United Kingdom / Cancer Research UK / / 9805; United Kingdom / Department of Health / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: These 46 patients included 44 esophageal squamous cell carcinomas,1 esophageal adenocarcinoma and 1 esophageal carcinoid.

All the patients were classified according to UICC TNM stage classification: 3 cases as stage 0, 6 cases as stage I, 17 cases as stage II a, 2 cases as stage II b, 16 cases as stage III.

Reconstruction with stomach was performed in 42 cases and with colon interposition in 4 cases.All the tumors were resected, and there was no perioperative death.

Genetic Alliance. consumer health - Esophageal Cancer.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18803048.001).

[ISSN] 1671-0274

[Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

[ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Evaluation Studies; Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.

The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.

METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.

RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.

Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.

The corresponding percentages with stage III were 93.6% and 1.4%.

In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.

For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.

CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.

On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

(PMID = 20079591.001).

[ISSN] 0399-8320

[Journal-full-title] Gastroentérologie clinique et biologique

[ISO-abbreviation] Gastroenterol. Clin. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] France

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.

In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.

Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.

[MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]

[Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]

[Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]

[Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]

[Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]

[Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]

[Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]

[Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]

[Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]

[Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]

[Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]

[Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]

[Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]

[Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]

[Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]

[Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]

[Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]

[Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]

[Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]

[Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]

[Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]

[Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]

[Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]

[Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]

[Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]

[Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]

[Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]

[Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]

[Cites] BMC Cancer. 2006;6:241 [17029629.001]

[Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]

[Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]

[Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]

[Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]

[Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]

[Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]

[Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]

[Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]

[Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]

(PMID = 17375048.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin

[Other-IDs] NLM/ PMC2360113

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical implications of fibroblast activation protein in patients with colon cancer.

PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor associated fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.

The primary objective of this study was to evaluate the clinical significance of stromal FAP in human colon cancers by immunohistochemisty.

EXPERIMENTAL DESIGN: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.

RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients.

Stromal FAP was found to correlate inversely with tumor stage (semiquantitative, P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coefficient, -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.

CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.

It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.

[MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Serine Endopeptidases / genetics

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17363526.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA006927; United States / NCI NIH HHS / CA / CA09035; United States / NCI NIH HHS / CA / CA090468; United States / NCI NIH HHS / CA / CA103991; United States / PHS HHS / / W81XWH-04-1-0709

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

SRC and MA are more likely to have locally advanced lesions (T3/T4; SRC 100%, MA 90%, OA 83%, p = 0.002) and lymph node metastases (SRC 89%, MA 61%, OA 52%, p < 0.0001) and present with an advanced stage at diagnosis (stage III/IV SRC 94%, MA 67%, OA 56%, p < 0.0001).

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / diagnosis. Mucins / analysis

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Surg Oncol. 2000 Oct;75(2):103-7 [11064389.001]

[Cites] Int J Oncol. 2009 Apr;34(4):1109-15 [19287969.001]

[Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]

[Cites] Dis Colon Rectum. 2008 Jan;51(1):50-5 [18030531.001]

[Cites] Clin Cancer Res. 2003 Nov 15;9(15):5660-5 [14654549.001]

[Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]

[Cites] Dis Colon Rectum. 2004 Jan;47(1):78-85 [14719155.001]

[Cites] Int J Colorectal Dis. 2004 Mar;19(2):102-7 [14752674.001]

[Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9 [17153438.001]

[Cites] J Surg Oncol. 2001 Aug;77(4):282-3 [11473380.001]

[Cites] Gastroenterol Hepatol. 2002 Nov;25(9):534-40 [12435303.001]

[Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]

[Cites] Dis Colon Rectum. 2006 Sep;49(9):1275-83 [16912910.001]

[Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]

[Cites] Am J Surg. 2007 Sep;194(3):294-8 [17693269.001]

[Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]

[Cites] J Surg Oncol. 2000 Feb;73(2):70-4 [10694641.001]

[Cites] Chin Med J (Engl). 2009 Jul 5;122(13):1486-91 [19719934.001]

[Cites] Cancer Lett. 1996 Jun 5;103(2):163-70 [8635153.001]

[Cites] Dis Colon Rectum. 1993 Jan;36(1):49-54 [8380140.001]

[Cites] J Pathol. 2007 Jul;212(3):278-86 [17471475.001]

[Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s123-5 [15655594.001]

[Cites] Med Arh. 2007;61(1):26-9 [17582971.001]

[Cites] J Gastroenterol Hepatol. 1996 Jan;11(1):77-81 [8672747.001]

[Cites] Dis Colon Rectum. 1999 Dec;42(12):1618-25 [10613484.001]

[Cites] Dis Colon Rectum. 2003 Feb;46(2):160-7 [12576888.001]

[Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]

(PMID = 20686777.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Mucins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In a subset analysis comparing patients with node-negative disease with patients with stage III disease, the 5-year disease-free survival rate was 56% for stage III patients versus 29% for patients with node-negative, PNI-positive tumors (P = .0002).

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Peripheral Nerves / pathology

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Laryngoscope. 1986 Oct;96(10):1145-8 [3762289.001]

[Cites] Head Neck Surg. 1986 Jul-Aug;8(6):401-8 [3721882.001]

[Cites] Dis Colon Rectum. 1991 Sep;34(9):798-804 [1914747.001]

[Cites] Br J Cancer. 1992 Jan;65(1):102-7 [1733432.001]

[Cites] Am J Surg Pathol. 1993 Apr;17(4):336-41 [8494103.001]

[Cites] Br J Surg. 1996 Jan;83(1):46-50 [8653361.001]

[Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]

[Cites] Cancer. 1996 Sep 15;78(6):1267-71 [8826950.001]

[Cites] Dis Colon Rectum. 1997 Mar;40(3):326-31 [9118749.001]

[Cites] J Surg Oncol. 1997 Jul;65(3):164-70 [9236924.001]

[Cites] Mol Cell Endocrinol. 1997 Oct 31;134(1):15-22 [9406845.001]

[Cites] Oncol Rep. 1998 Jan-Feb;5(1):73-6 [9458297.001]

[Cites] Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40 [9639472.001]

[Cites] Am J Surg. 1999 May;177(5):392-5 [10365877.001]

[Cites] Clin Exp Metastasis. 2004;21(4):285-92 [15554384.001]

[Cites] Arch Pathol Lab Med. 2005 Mar;129(3):354-9 [15737030.001]

[Cites] Cell Death Differ. 2005 Aug;12(8):1044-56 [16015381.001]

[Cites] Cancer. 2007 Jan 1;109(1):13-24 [17123267.001]

[Cites] Am J Clin Oncol. 2007 Feb;30(1):93-6 [17278901.001]

[Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]

[Cites] Dis Colon Rectum. 2008 May;51(5):503-7 [18322753.001]

[Cites] Colorectal Dis. 2008 Nov;10(9):879-86 [19037929.001]

[Cites] Acta Chir Iugosl. 2008;55(3):39-44 [19069691.001]

[Cites] Cancer. 2009 Aug 1;115(15):3379-91 [19484787.001]

[Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):34-63 [16019758.001]

[Cites] Cancer. 1988 Mar 1;61(5):1018-23 [3338045.001]

[Cites] Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7 [4026129.001]

[Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]

[Cites] Urology. 1999 Dec;54(6):1039-43 [10604705.001]

[Cites] J Urol. 2001 Jan;165(1):114-8 [11125378.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G958-67 [11292605.001]

[Cites] Eur Urol. 2001 Sep;40(3):308-12 [11684847.001]

[Cites] Dis Colon Rectum. 2001 Nov;44(11):1682-8 [11711742.001]

[Cites] Prostate. 2001 Nov 1;49(3):213-23 [11746267.001]

[Cites] Digestion. 2002;66(2):79-88 [12428066.001]

[Cites] Urology. 2003 Apr;61(4):870-5 [12670591.001]

[Cites] Pancreas. 2003 May;26(4):322-5 [12717262.001]

[Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 [14697416.001]

[Cites] Jpn J Clin Oncol. 2004 Jun;34(6):323-8 [15333684.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):6082-90 [15342391.001]

[Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Sep;280(1):821-6 [15382019.001]

[CommentIn] Z Gastroenterol. 2010 Dec;48(12):1405-6 [21125515.001]

[CommentIn] J Clin Oncol. 2010 Jul 20;28(21):e358-60; author reply e361-2 [20385977.001]

(PMID = 19738119.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Other-IDs] NLM/ PMC2773472

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Inadequate quality of surveillance after curative surgery for colon cancer.

BACKGROUND: Colon cancer patients are at risk for recurrence.

The objective of this study is to analyze the quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients.

PATIENTS AND METHODS: After curative surgery, 129 stage I-III colon cancer patients were followed by chart review, questionnaires, and phone interviews.

CONCLUSIONS: The quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients is inadequate.

[MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Continuity of Patient Care

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20429036.001).

[ISSN] 1534-4681

[Journal-full-title] Annals of surgical oncology

[ISO-abbreviation] Ann. Surg. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Carcinoembryonic Antigen

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] Lymphadenektomie bei Tumoren des unteren Gastrointestinaltraktes.

Following these rules and with no adjuvant systemic treatment, 5-year survival figures of 80% can be reached, even for UICC stage III disease.

[MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Intestines / pathology. Intestines / surgery. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Staging. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Prognosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]

[Cites] Jpn J Surg. 1983 Nov;13(6):557-73 [6672390.001]

[Cites] Fortschr Med. 1986 Feb 27;104(8):167-70 [3957212.001]

[Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]

[Cites] Chirurg. 2003 Oct;74(10):897-904 [14605731.001]

[Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]

[Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]

[Cites] Langenbecks Arch Surg. 1998 Dec;383(6):402-8 [9921939.001]

[Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]

[Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]

[Cites] Br J Surg. 2003 Dec;90(12):1580-5 [14648739.001]

[Cites] J Am Coll Surg. 1997 Jun;184(6):584-8 [9179114.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]

[Cites] World J Surg. 1996 Feb;20(2):132-41 [8661808.001]

[Cites] Chirurg. 2004 Aug;75(8):761-6 [15232693.001]

[Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]

[Cites] Am J Surg. 2006 Mar;191(3):305-10 [16490536.001]

[Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]

[Cites] Z Gastroenterol. 2004 Sep;42(9):1067-72 [15455287.001]

[Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]

[Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]

[Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]

[Cites] Chirurg. 2007 Aug;78(8):739-47 [17569018.001]

[Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]

[Cites] J R Soc Med. 1988 Sep;81(9):503-8 [3184105.001]

[Cites] Surg Endosc. 1989;3(2):96-9 [2672395.001]

[Cites] J Am Coll Surg. 1997 May;184(5):475-80 [9145067.001]

[Cites] Digestion. 1994;55 Suppl 3:11-23 [7698533.001]

[Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]

[Cites] Scand J Surg. 2003;92(1):45-52 [12705550.001]

[Cites] Chirurg. 2006 Jan;77(1):33-40 [16372188.001]

[Cites] J Clin Oncol. 2003 Jul 15;21(14):2740-6 [12860953.001]

(PMID = 17333036.001).

[ISSN] 0009-4722

[Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen

[ISO-abbreviation] Chirurg

[Language] ger

[Publication-type] English Abstract; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Medullary carcinoma (MC) of the colorectum is a relatively new histological type of adenocarcinoma characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate.

We observed that MCs were rare tumors, constituting approximately 5-8 cases for every 10,000 colon cancers diagnosed, with a mean annual incidence of 3.47 (+/-0.75) per 10 million population.

MCs were twice as common in females, who presented at a later age, with a lower stage and a trend towards favorable prognosis.

MCs were most common in the proximal colon (74%), where they present at a later age than the sigmoid colon.

MCs commonly presented with Stage II disease, with 10% presenting with metastases.

Although MCs showed a trend towards better early overall survival, undifferentiated MCs present more commonly with Stage III, with comparatively worse early outcomes.

[MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Colorectal Neoplasms / epidemiology

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 1999 Aug;17(8):2429-38 [10561306.001]

[Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]

[Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]

[Cites] Histopathology. 1977 Jan;1(1):77-84 [615835.001]

[Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]

[Cites] J Clin Oncol. 2010 Jan 10;28(2):264-71 [19949014.001]

[Cites] Hum Pathol. 1999 Jul;30(7):843-8 [10414504.001]

[Cites] Am J Clin Pathol. 2005 Jan;123(1):56-65 [15762280.001]

[Cites] Hum Pathol. 2009 Mar;40(3):398-404 [18992917.001]

[Cites] Oncology (Williston Park). 2009 Mar;23(3):288-95 [19418830.001]

[Cites] Am J Pathol. 1997 May;150(5):1815-25 [9137104.001]

(PMID = 20811712.001).

[ISSN] 1791-2423

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / T32 CA113263

[Publication-type] Comparative Study; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Carcinoembryonic Antigen

[Other-IDs] NLM/ NIHMS609288; NLM/ PMC4127912

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.

BACKGROUND: Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrence and improves survival.

PATIENTS AND METHODS: Patients with a curatively resected UICC stage III colon cancer were stratified according to T, N and G category and randomly assigned to receive one of the three adjuvant treatment schemes: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles, arm A; 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications, arm B; 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications, arm C.

CONCLUSION: There is no statistical difference in efficacy and toxicity in patients receiving either high-dose 5-FU with or without leucovorin or the standard 5-FU bolus regime after a curative resection of a stage III colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Colectomy / methods. Colonic Neoplasms / drug therapy. Fluorouracil / administration & dosage. Leucovorin / administration & dosage

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Minerva Chir. 2003 Aug;58(4):491-502, 502-7 [14603161.001]

[Cites] Ann Oncol. 2003 Mar;14(3):395-9 [12598344.001]

[Cites] Ann Oncol. 1996 Jan;7(1):42-6 [9081390.001]

[Cites] J Clin Oncol. 2001 Mar 15;19(6):1787-94 [11251010.001]

[Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3277-83 [15249584.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] J Clin Oncol. 1995 Jun;13(6):1303-11 [7751875.001]

[Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]

[Cites] Int J Cancer. 1995 Sep 27;63(1):43-8 [7558450.001]

[Cites] J Clin Oncol. 1991 Apr;9(4):625-30 [2066758.001]

[Cites] Chirurg. 1994 Apr;65(4):287-97 [8020349.001]

(PMID = 15549327.001).

[ISSN] 0179-1958

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] Germany

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil